ʻO Remdesivir kahi lāʻau antiviral e kuhikuhi ana i nā ʻano maʻi. Ua hoʻokumu mua ʻia ma mua o hoʻokahi mau makahiki i hala aku nei e mālama i ka maʻi hepa C a me kahi maʻi like ʻole i kapa ʻia ʻo respiratory syncytial virus (RSV). ʻAʻole ʻo Remdesivir kahi lāʻau lapaʻau maikaʻi no kēlā me kēia maʻi. Akā ua hōʻike ʻo ia i ka hoʻohiki kūʻē i nā maʻi ʻē aʻe.

Ua hoʻāʻo nā mea noiʻi i ka remdesivir i nā hoʻokolohua lapaʻau i ka wā o ka maʻi Ebola. Ua ʻoi aku ka maikaʻi o nā lāʻau noiʻi ʻē aʻe, akā ua hōʻike ʻia he palekana no nā maʻi. Ua hōʻike ʻia nā haʻawina i loko o nā cell a me nā holoholona he hopena maikaʻi ka remdesivir e kūʻē i nā maʻi i loko o ka ʻohana coronavirus, e like me Middle East Respiratory Syndrome (MERS) a me Severe Acute Respiratory Syndrome (SARS).

Hana ʻo Remdesivir ma ka hoʻopau ʻana i ka hana ʻana o ka maʻi. Loaʻa i nā coronaviruses nā genomes i hana ʻia ka ribonucleic acid (RNA). Hoʻopilikia ʻo Remdesivir i kekahi o nā enzyme koʻikoʻi e pono ai ka maʻi e hana hou i ka RNA. Kāohi kēia i ka maʻi virus mai ka hoʻonui ʻana.

Ua hoʻomaka ka poʻe noiʻi i ka hoʻāʻo ʻana o ka antiviral i Pepeluali 2020 e hoʻāʻo ai inā hiki ke hoʻohana ʻia ka remdesivir e mālama i ka SARS-CoV-2, ka coronavirus e kumu ai ka COVID-19. Ma ʻApelila,nā hopena muaUa hōʻike ʻo remdesivir i ka wikiwiki o ka hoʻihoʻi ʻana i nā maʻi maʻi maʻi me COVID-19 koʻikoʻi. Ua lilo ia i lāʻau lapaʻau mua e loaʻa ai ka ʻae ʻana i ka hoʻohana ʻana i ka pilikia mai ka US Food and Drug Administration (FDA) e mālama i ka poʻe i mālama ʻia me COVID-19.

Ua hoʻopau nā mea noiʻi i ka hoʻokolokolo, i kapa ʻia ʻo Adaptive COVID-19 Treatment Trial (ACTT-1). Ua kākoʻo ʻia ke aʻo ʻana e ka National Institute of Allergy and Infectious Diseases (NIAID). Ua puka mai ka hoike hope ma kaʻO ka New England Journal of Medicinema ʻOkakopa 8, 2020.